Tiffany Gould

Tiffany Gould

Auto-generated profile, based on publicly available information

Tiffany Gould

Division of Surgery, John Hunter Hospital, Newcastle, New South Wales, Australia; School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia; Hunter Medical Research Institute, Newcastle, Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Journal of Surgical Research
Verified
Journal Article
Closed access
JPJoel Petit
Joel Petit
GCGeorgia Carroll
Georgia Carroll
TGTiffany Gould
Tiffany Gould
PPPeter Pockney
Peter Pockney
Matthew DunMatthew Dun
Matthew Dun
RSRodney J. Scott
Rodney J. Scott

1 February 2020 in Journal of Surgical Research
Verified
Journal Article
Closed access
DEDilharan D. Eliezer
Dilharan D. Eliezer
MHMerran Holmes
Merran Holmes
GSGavin Sullivan
Gavin Sullivan
JGJon Gani
Jon Gani
PPPeter Pockney
Peter Pockney
GFGabrielle Francis
Gabrielle Francis

6 February 2019
Verified
Book Chapter
Open access
PDF file
TGTiffany Gould
Tiffany Gould
MJMuhammad Fairuz Jamaluddin
Muhammad Fairuz Jamaluddin
JPJoel Petit
Joel Petit
SKSimon J. King
Simon J. King
BNBrett Nixon
Brett Nixon
Matthew DunMatthew Dun
Matthew Dun
Colorectal cancer (CRC) is a common and treatable disease if diagnosed early. Current population screening programs are suboptimal, and consequently, there is a need for the development of new methodologies for early diagnosis of CRC. In the past 10 years, unprecedented technological advancements in the field of mass spectrometry (MS)-based proteomics have progressively increased the sophistication and utility of these investigations, leading to the draft mapping of the human proteome. These exciting studies have shaped our mechanistic understanding of the human genome and begun to provide us with a suite of novel biomarkers to predict the onset, progression and severity of many debilitating diseases. Thus, sophisticated MS workflows coupled with revolutionary protein quantification techniques hold promise for the field of MS-based plasma proteomics, particularly valuable in the context of early stage identification of curable CRC. However, within the last 40 years, no new plasma protein biomarkers of CRC have been translated into clinical practice. Here. we discuss the application of proteomic technologies within the field of CRC, highlighting contemporary MS-based plasma proteomic strategies that could be exploited to deliver on the promise of a panel of sensitive and specific plasma-based biomarkers with which to non-invasively detect early stage CRC.